Azithromycin's unique pharmacokinetic characteristic distinguishes it from clarithromycin and erythromycin. Which property is primarily responsible for its once-daily, short-course (3-5 day) dosing schedule?
- A High plasma protein binding reducing volume of distribution
- B Extensive tissue accumulation (high Vd ~31 L/kg) with intracellular drug concentrations far exceeding plasma levels, and slow release from tissues producing a prolonged tissue half-life of 68 hours ✓
- C Inhibition of CYP3A4 reducing its own metabolism and prolonging plasma half-life
- D Renal excretion as unchanged drug with a terminal elimination half-life of 2-3 hours
Explanation
Azithromycin has an exceptionally large volume of distribution (~31 L/kg) due to extensive uptake into tissue macrophages, phagocytes, and intracellular compartments. Tissue concentrations can be 100-fold greater than plasma concentrations. It is released slowly from tissues over days, producing a tissue half-life of approximately 68–76 hours compared to its plasma half-life of ~11–14 hours. This 'tissue depot' explains why a 3-day or 5-day course (with the loading dose strategy) achieves effective tissue concentrations for 7–10 days at the infection site. Unlike clarithromycin, azithromycin does NOT significantly inhibit CYP3A4, resulting in fewer drug-drug interactions.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.